Short Bowel Syndrome Treatment Market Expands with Rising Gastrointestinal Disorders, Persistence Market Research

The global Short Bowel Syndrome (SBS) treatment market is emerging as a critical segment within the rare gastrointestinal disorder space, driven by rising surgical interventions, expanding clinical awareness, and accelerating innovation in targeted biologic therapies. Short bowel syndrome is a complex malabsorptive condition resulting from extensive surgical resection of the small intestine or severe intestinal disease, leading to inadequate absorption of fluids, electrolytes, and nutrients. Patients often face lifelong complications such as chronic diarrhea, dehydration, micronutrient deficiencies, and significant weight loss, making long-term medical management essential. Historically, treatment relied heavily on parenteral nutrition and symptomatic control, but recent advances in hormone-based therapies have redefined the treatment paradigm.

Download Your Free Sample & Explore Key Insights: https://www.persistencemarketresearch.com/samples/35947

From a market perspective, the global short bowel syndrome treatment market size is valued at US$1,320.8 million in 2025 and is forecast to reach US$2,150.3 million by 2032, expanding at a compound annual growth rate (CAGR) of 7.2% over the forecast period. This sustained growth reflects increasing adoption of glucagon-like peptide-2 (GLP-2) analogs, improved diagnostic pathways, and supportive reimbursement frameworks for orphan diseases. Among treatment categories, GLP-2-based therapies dominate with an estimated 87.4% market share, owing to their proven ability to enhance intestinal adaptation and reduce dependence on parenteral nutrition. North America leads the global market with a 47.1% share, supported by advanced healthcare infrastructure, strong rare-disease reimbursement systems, and high physician adoption of novel biologics, while Asia Pacific emerges as the fastest-growing region, driven by healthcare expansion and rising clinical recognition of SBS.

Key Highlights from the Report

• The global short bowel syndrome treatment market is projected to grow at a robust CAGR of 7.2% between 2025 and 2032.
• Glucagon-like peptide-2 therapies account for over 87% of total market revenue due to superior clinical outcomes.
• North America dominates the market with a 47.1% share, supported by strong reimbursement and biologic adoption.
• Hospital pharmacies remain the leading distribution channel, holding more than 68% of market value.
• Asia Pacific is the fastest-growing regional market with a projected CAGR of 9.0%.
• Increasing clinical trial activity for long-acting and oral GLP-2 analogs is reshaping future treatment standards.

Market Segmentation Analysis

The short bowel syndrome treatment market is segmented primarily based on product type, distribution channel, and end-user setting, each playing a distinct role in shaping overall market dynamics. By product type, glucagon-like peptide-based therapies form the backbone of modern SBS management, offering mechanism-driven benefits that address the underlying pathophysiology of intestinal failure. These therapies promote mucosal growth, enhance absorptive capacity, and significantly reduce reliance on parenteral nutrition. Supportive therapies, including antidiarrheals, proton pump inhibitors, growth hormones, and customized parenteral nutrition formulations, continue to serve as essential adjuncts, particularly in early disease stages or in patients with partial intestinal adaptation.

Based on distribution channels, hospital pharmacies dominate the market, reflecting the complex and highly supervised nature of SBS treatment. Initiation of GLP-2 analog therapy typically occurs in tertiary care settings, where multidisciplinary teams monitor dosing, nutritional status, and intestinal response. Cold-chain requirements, prescription validation, and frequent clinical monitoring further reinforce hospital-based dispensing. Retail and specialty pharmacies play a more limited role, primarily supporting maintenance therapy in stable patients receiving home-based care.

From an end-user perspective, specialized hospitals and intestinal rehabilitation centers represent the largest consumer base, as SBS management requires coordinated care involving gastroenterologists, surgeons, dietitians, and endocrinologists. Home care settings are gaining importance as advancements in parenteral nutrition and biologic therapies enable more patients to transition to outpatient or home-based management, improving quality of life and reducing long-term healthcare costs.

Regional Insights and Market Performance
North America Market Trends

North America represents the most mature and dominant regional market for short bowel syndrome treatment, accounting for approximately 47.1% of global revenue in 2025. The region benefits from high disease awareness, early diagnosis, and widespread adoption of advanced biologics, particularly GLP-2 analogs. In the United States alone, an estimated 10,000 to 20,000 individuals live with SBS, with prevalence closely linked to high rates of small bowel resections and chronic gastrointestinal disorders. Strong payer support for orphan drugs, coupled with established home parenteral nutrition programs, continues to drive sustained market growth across both adult and pediatric populations.

Europe Market Trends

Europe holds nearly 24.4% of the global SBS treatment market, supported by well-developed clinical infrastructure and early adoption of intestinal rehabilitation strategies. SBS accounts for a significant proportion of intestinal failure cases across the region, necessitating long-term nutritional and pharmacological management. The presence of dedicated intestinal rehabilitation programs and EU-funded research initiatives aimed at regenerative therapies strengthens Europe's position as a key innovation hub. Public healthcare coverage for rare diseases and collaborative research networks further enhance market stability and long-term growth potential.

Asia Pacific Market Trends

The Asia Pacific short bowel syndrome treatment market is poised for rapid expansion, projected to grow at a CAGR of 9.0% during the forecast period. Rising gastrointestinal surgical volumes, improving diagnostic capabilities, and increasing access to specialist care are driving demand across major economies such as China, Japan, South Korea, and Australia. Government initiatives focused on rare-disease management, combined with growing adoption of GLP-2 analogs and customized parenteral nutrition, are transforming the regional treatment landscape. As awareness improves and reimbursement pathways expand, Asia Pacific is expected to become a major growth engine for the global market.

Get Custom Insights Designed for Your Business: https://www.persistencemarketresearch.com/request-customization/35947

Market Drivers

The primary driver of the short bowel syndrome treatment market is the advancement of GLP-2-based therapies, which directly address intestinal adaptation and nutrient absorption deficits. Increasing clinical awareness, improved epidemiological data, and supportive orphan-drug policies have encouraged pharmaceutical companies to invest heavily in SBS-focused research and development. Growing collaboration between non-profit organizations, regulatory bodies, and industry stakeholders has accelerated clinical trial activity and expanded treatment access. Innovations in parenteral nutrition formulations and multidisciplinary care models further support long-term disease management, reinforcing sustained market growth.

Market Restraints

Despite positive momentum, the market faces notable restraints, particularly high treatment costs and limited access to advanced therapies in developing regions. GLP-2 analogs and long-term parenteral nutrition impose significant financial burdens on healthcare systems and patients, limiting widespread adoption. Regulatory delays, such as requests for additional confirmatory trials, can slow product approvals and dampen near-term growth. Additionally, uneven physician awareness and limited specialist availability in community settings continue to hinder early diagnosis and optimal treatment initiation.

Market Opportunities

Significant opportunities lie in the development of next-generation long-acting and oral GLP-2 therapies, which promise improved patient compliance and broader accessibility. Emerging once-weekly injectables and oral formulations have the potential to reduce treatment burden and expand the eligible patient population. Growing interest in pediatric SBS management, combined with expanding reimbursement frameworks in emerging markets, further enhances commercial prospects. As research pipelines mature and clinical evidence strengthens, SBS treatment is evolving into a high-value therapeutic area with long-term growth potential.

Checkout Now & Download Complete Market Report: https://www.persistencemarketresearch.com/checkout/35947

Company Insights

The competitive landscape of the short bowel syndrome treatment market is characterized by a limited number of specialized players focusing on biologics, supportive therapies, and innovative delivery platforms.

• OPKO Health, Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Ironwood
• Entera Bio Ltd.
• Zealand Pharma
• Emmaus Medical, Inc.
• EMD Serono
• OxThera
• Jaguar Health

Market Segmentation

By Drug Class

Glucagon-like Peptide
Histamine Blockers
Proton Pump Inhibitors
Growth Hormone
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East and Africa

Recent developments in the market highlight ongoing innovation and pipeline expansion. In 2025, a first-in-class oral GLP-2 tablet is scheduled for presentation at a major European clinical nutrition congress, signaling progress toward more patient-friendly therapies. Additionally, early-stage pediatric trials exploring novel symptomatic treatments have shown promising results, potentially supporting expanded access and reimbursement in select markets.

Conclusion

The global short bowel syndrome treatment market is undergoing a meaningful transformation, shifting from supportive care dominance to mechanism-driven, biologic-focused management. Strong market growth is underpinned by rising disease awareness, expanding surgical prevalence, and sustained innovation in GLP-2 analog therapies. While high costs and regulatory hurdles remain challenges, ongoing advancements in long-acting and oral treatment platforms present compelling opportunities for future expansion. With North America leading adoption, Europe strengthening research initiatives, and Asia Pacific emerging as a high-growth region, the SBS treatment market is well-positioned for sustained development through 2032, offering improved outcomes and quality of life for patients worldwide.

Read More Related Reports:

Neonatal Infant Care Market https://www.persistencemarketresearch.com/market-research/neonatal-infant-care-market.asp
Herpes Marker Testing Market https://www.persistencemarketresearch.com/market-research/herpes-markers-testing-market.asp
Cardiovascular Information Systems (CVIS) Market https://www.persistencemarketresearch.com/market-research/cardiovascular-information-systems-market.asp
Attention Deficit Hyperactivity Disorder Therapeutics Market https://www.persistencemarketresearch.com/market-research/attention-deficit-hyperactivity-disorder-therapeutics-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.